Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatropin Therapy for Short Children Born Prematurely (AGA)
NCT00174460Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2005
- Primary completion
- Mar 2008
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of somatropin in short stature (2 arms), sponsored by Pfizer. Primary endpoints: Change in Height Standard Deviation Score at 1 year and Change in Growth Velocity Standard Deviation Score at 1 year. Started Aug 2005; status: completed.
02
Drugs
somatropin
03
Conditions
short stature
Beyond the preview
Go deeper on NCT00174460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174460.